2025 Publications

240. Li, Y. and Liang, S. H. “Selective Modulation of the GluN2B/C/D Containing N-Methyl-d-Aspartate Receptors: A New Frontier in Targeted Neurotherapeutics”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00365

 

239. Liang, S. H. “Trop2-Targeted ImmunoPET Ligands”, American Journal of Nuclear Medicine and Molecular Imaging, accepted.

 

238. Zhao, T. and Liang, S. H. “Streamlining First-in-Human PET Radiopharmaceutical Development: FDA’s Evolving Stance on Preclinical Dosimetry”, American Journal of Nuclear Medicine and Molecular Imaging, accepted.

 

237. Zhao, T. and Liang, S. H. “Novel Tracers and Emerging Targets for Positron Emission Tomography in Alzheimer’s Disease and Related Dementias”, American Journal of Nuclear Medicine and Molecular Imaging, accepted.

236. Liang, S. H. “DLL3-Targeted ImmunoPET and Radioimmunotherapy Ligands”, American Journal of Nuclear Medicine and Molecular Imaging, accepted.

 

235. Li, C.; Song, Z.; Hu, Q.; Li, Y.; Patel, J. S.; Liang, S. H. “CD45-targeted PET enables the visualization of inflammatory conditions”, American Journal of Nuclear Medicine and Molecular Imaging, accepted.

 

234. Li, Y.; Dahl, K.; Elmore, C. S.; Sandell, J.; Takano, A.; Halldin, C.; Farde, L.; Ahlgren, C.; Cochrane, A.; Rong, J.; Chen, J.; Zhao, C.; Zhou, X.; Patel, J. S.; Song, Z.; Chaudhary, A.; Gao, Y.; Sun, Z.; Zhang, Z.; Feng, S.; Haider, A.; Liang, S. H.; Schou, M. “Radiosynthesis and Evaluation of 11C-Labeled Imidazolyl Pyrimidine Derivatives for Positron Emission Tomography Imaging of Glycogen Synthase Kinase-3”, ACS Pharmacology & Translational Science, accepted.

 

 233. Li, Y. and Liang, S. H. “Novel Isoindolin-1-one Derivatives as Metabotropic Glutamate Receptor Positive Allosteric Modulators”, ACS Medicinal Chemistry Letters, 2025, accepted.

232. Zhou, X. and Liang, S. H. “Targeted Treatment of Cancer by Using Conjugate Compounds with Poly(ADP-ribose) Polymerase (PARP) Inhibitors”, ACS Medicinal Chemistry Letters, 2025, accepted.

231. Zhou, X. and Liang, S. H. “Synthesis of Novel Substituted N-heterocycles and Their Use of Selective Poly(ADP-ribose) Polymerase 1 (PARP1) Inhibitors”, ACS Medicinal Chemistry Letters, 2025, accepted.

230. Liang, S. H. “Novel Heterocyclic 5H-dibenzo[b,f]azepine Derivatives as Selective HDAC6 inhibitors for Treatment of Charcot Marie Tooth Disease”, ACS Medicinal Chemistry Letters, 2025, accepted.

229. Liang, S. H. “Novel (1H-Pyrazol-4-ylamino)pyrimidine Derivatives as Wee1 Inhibitors for Treatment of Cancer”, ACS Medicinal Chemistry Letters, 2025. accepted.

228. Ran, W.; Hu, K.; Ye, W.; Zhang, L.; Chen, J.; Ji, B.; Mori, W.; Wang, Z.; Lu, H.; Haider, A.; Yamasaki, T.; Huang, H.; Xie, L.; Yang, Q.; Yuan, S.; Wang, X.; Gong, J.; Wang, H.; Liang, S. H.; Wang, J.; Wang, R.; Zhang, M. R. and Wang, L. “Radiofluorination of 2-Arylquinolin-4-yl Oxypropanamide Derivatives for TSPO Imaging in Neuroinflammatory Murine, Nonhuman Primates, and Human Brain Autoradiography with Insensitivity to the rs6971 Polymorphism”, Journal of Medicinal Chemistry, 2025. ASAP. https://pubmed.ncbi.nlm.nih.gov/40489695/

 

227. Zhou, X.; Chen, J.; Patel, J. S.; Ran, W.; Li, Y.; Van, R. S.; Ibrahim, M. M. H.; Zhao, C.; Gao, Y.; Rong, J.; Chaudhary, A. F.; Li, G.; Hu, J.; Davenport, A. T.; Daunais, J. B.; Shao, Y.; Ran, C.; Collier, T. L.; Haider, A.; Schuster, D. M.; Levey, A.; Wang, L.; Corfas, G. and Liang, S. H. “Imaging poly(ADP-ribose) polymerase-1 (PARP1) in vivo with 18F-labeled brain penetrant positron emission tomography (PET) ligand”, Acta Pharmaceutica Sinica B, 2025. https://www.sciencedirect.com/science/article/pii/S2211383525003260

 

226. Shao, T.; Gu, Z.; Liu, Y.; Wang, X.; Tang, C.; Chen, N.; Wang, M.; Liu, X.; Song, H.; Chen, S.; Li, W.; Hui, H.; Jia, X.; Mao, H.; Chung, R. T.; Liang, S. H.; Xiong, S. and Tian, J. “Long-term in vivo monitoring of transplanted mesenchymal stromal cells in colitis mice with magnetic particle imaging”, EBioMedicine, 2025, 116, 105775. https://pubmed.ncbi.nlm.nih.gov/40435720/

 

225. Song, Z. and Liang, S. H. “Novel Tetrahydrocyclohepteneindole Derivatives Targeting Estrogen Receptor Alpha for the Treatment of Breast Cancer”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00283

224. Hu, Q-L. and Liang, S. H. “Deuterated 1,3 Dihydro-2H-indole-2-one Derivatives for Treatment of Depression or Anxiety”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00284

223. Zhou, X. and Liang, S. H. “Synthesis and Application of Novel Arginine Vasopressin Receptor 1A (AVPR1A) Antagonists”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00285

222. Rong, J. and Liang, S. H. “Novel 2,6,9-Trisubstituted Purines as CDK2 Inhibitors for Treating Cancers”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00282

221. Liang, J.; Weng, S.; Zhang, J.; Jiang, S.; Li, W.; Li, S.; Rong, J.; Liu, H.; Chen, H.; Liu, Z.; Peng, H.; Yan, S.; Zhang, R.; Liang, S. H. and Zhang, L. “Diagnostic performance of [18F]FAPI-04 PET/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT/MRI”, European Journal of Nuclear Medicine and Molecular Imaging, 2025. Online ahead of print. Link: https://pubmed.ncbi.nlm.nih.gov/40232335/

figure 2

 

220. Dong, C.; Ye, W.; Xu, Y.; Chen, J.; Liao, K.; Wei, H.; Jiang, Y.; Hou, L.; Wei, J.; Tan, Z.; Song, Z.; Li, Y.; Haider, A.; Yuan, H.; Liang, S. H. and Wang, L. “Automatic synthesis of a phosphodiesterase 4B (PDE4B) radioligand and PET imaging in depression rodent models”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15, 55-64. Link: https://pubmed.ncbi.nlm.nih.gov/40401108/

219. Feng, S. and Liang, S. H. “Novel Sulfonamide Derivatives as Nav1.5 Sodium Channel Blockers for Treating Atrial Fibrillation”, ACS Medicinal Chemistry Letters, 2025, 16, 748-749. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00192

218. Song, Z. and Liang, S. H. “Novel Tetrahydrobenzo[b]pyrazolo[3,4-e][1,4]diazepine Compounds as Oxytocin Receptor Agonists for Treating Autism Spectrum Disorders”, ACS Medicinal Chemistry Letters, 2025, 16, 752-753. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00190

217. Li, Y. and Liang, S. H. “Novel Nonpeptide as Oxytocin Receptor Agonist”, ACS Medicinal Chemistry Letters, 2025, 16, 750-751. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00191

216. Li, Y. and Liang, S. H. “Novel Tricyclic Compounds as GSK3 Inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 724-727. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00162

215. Li, Y. and Liang, S. H. “Novel Heterocyclic Pyrimidine Derivatives as GSK3α Inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 721-723. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00159

214. Song, Z. and Liang, S. H. “Novel Azaindole Compounds as Phosphodiesterase 4B Inhibitors for Treating Immune-Inflammatory Diseases or Disorders”, ACS Medicinal Chemistry Letters, 2025, 16, 717-718. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00158

213. Li, Y. and Liang, S. H. “Novel 2-Pyrrolidone Derivatives as Negative Allosteric Modulators of GluN2B-Containing NMDA Receptors”, ACS Medicinal Chemistry Letters, 2025, 16, 719-720. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00157.

212. Li, Y.; Yuan, H. and Liang, S. H. “Advances in the Structural Basis of GluN2A-Selective Negative Allosteric Modulators”, ACS Medicinal Chemistry Letters, 2025. ASAP. https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00226

 

211. Zhao, T. and Liang, S. H. “PDE7 as a Precision Target: Bridging Disease Modulation and Potential PET Imaging for Translational Medicine”, ACS Medicinal Chemistry Letters, 2025, 16, 711-714. DOI: 10.1021/acsmedchemlett.5c00160

 

210. Li, C.; Hu, Q. and Liang, S. H. “CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15, 37-43. DOI: 10.62347/VHYY2134. eCollection 2025

 

209. Zhao, T. and Liang, S. H. “Multivalent FAPI-based radiopharmaceuticals in PET/CT: from cancer diagnostics to theranostics”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15, 82-86. DOI: 10.62347/TUZI7617. eCollection 2025

 

208. Zhou, X. and Liang, S. H. “Preparation of Substituted Heterocycles and Their Use as DNA Polymerase Theta (POLQ) Inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 536-537. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00137

207. Zhao, T. and Liang, S. H. “Novel Triazole-Substituted Imidazo[1,2-a]Pyrimidine Compounds as cGAS inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 530-531. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00136

206. Hu, Q-L. and Liang, S. H. “Novel Cyclic Peptides as Interleukin-23 Inhibitor for Treating Inflammatory Disorders”, ACS Medicinal Chemistry Letters, 2025, 16, 532-533. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00135

205. Rong, J. and Liang, S. H. “Novel Pyrazolo[1,5-a]pyrimidine-3,5-diamines as nSMase2 Inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 534-535. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00134

204. Li, Y. and Liang, S. H. “6-Aryl Isoindolin-1-ones: Novel mGluR2 Negative Allosteric Modulators”, ACS Medicinal Chemistry Letters, 2025, 16, 512-513. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00106

203. Li, Y. and Liang, S. H. “Novel 6-Aryl isoindolin-1-one Derivatives as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 2”, ACS Medicinal Chemistry Letters, 2025, 16, 510-511. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00107

202. Zhao, T. and Liang, S. H. “Enhancing the Stability of 211At Radiopharmaceuticals: Insights from Ortho-Substituent Strategies”, ACS Medicinal Chemistry Letters, 2025, 16, 504–507. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00102

 

201. Bi, C.; Patel, J. S. and Liang, S. H. “Development of CD73 Inhibitors in Tumor Immunotherapy and Opportunities in Imaging and Combination Therapy”, Journal of Medicinal Chemistry, 2025, 68, 6860–6869. DOI: https://doi.org/10.1021/acs.jmedchem.4c021

 

200. Rong, J.; Zhao, C.; Chaudhary, A. F.; Chen, J.; Zhou, X.; Zhang, K.; Song, Z.; Sun, Z.; Gao, Y.; Zhang, Z.; Feng, S.; Collier, T. L.; Yuan, H.; Patel, J. S.; Haider, A.; Li, Y. and Liang, S. H. “Development of a Novel 18F-Labeled Radioligand for Imaging Cholesterol 24-Hydroxylase with Positron Emission Tomography”, ACS Pharmacology & Translational Science, 2025, 8, 800–807. DOI: https://pubs.acs.org/doi/10.1021/acsptsci.4c00683

 

199. Rong, J.; Zhao, C.; Chaudhary, A. F.; Jones, E.; Van, R.; Song, Z.; Li, Y.; Chen, J.; Zhou, X.; Patel, J. S.; Gao, Y.; Sun, Z.; Feng, S.; Zhang, Z.; Collier, T. L.; Ran, C.; Haider, A.; Shao, Y.; Yuan, H. and Liang, S. H. “Development of a Novel 18F-Labeled Radioligand for Imaging Phosphodiesterase 7 with Positron Emission Tomography”, Molecular Pharmaceutics, 2025, 22, 1657–1666. DOI: https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.4c01379

 

198. Pees, A.; Morrone, C. D.; Tong, J.; Rong, J.; Shao, T.; Wear, D.; Liang, S. H.; Yu, W. H.; Vasdev, N. “Sex- and age-specific sensitivities of the endocannabinoid system in Alzheimer’s disease revealed by PET imaging with [18F]FMPEP-d2 and [18F]MAGL-2102”, Theranostics, 2025, 15, 3368-3385. Link: https://www.thno.org/v15p3368.htm

 

197. Feng, S. and Liang, S. H. “Identification of Indazole- and Azaindazole-Substituted Cyclopentapyrroles as G2019S Leucine-Rich Repeat Kinase 2 Inhibitors for the Treatment of CNS Disorders”, ACS Medicinal Chemistry Letters, 2025, 16, 368–370. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00045

196. Rong, J.; Zhao, C.; Chaudhary, A. F.; Ware, T.; Van, R. S.; Li, Y.; Leon, E. R. C.; Dang, V.; Chen, J.; Xiao, Z.; Zhou, X.; Zhang, W.; Bi, C.; Zhang, K.; Patel, J. S.; Shao, Y.; Ran, C.; Collin, L.; Haider, A.; Cravatt, B. F. and Liang, S. H. “Development of a novel 18F-labeled reversiblebinding radioligand for imaging monoacylglycerol lipase with positron emission tomography”, Acta Pharmaceutica Sinica B, 2025, accepted.

 

195. Li, Y.; Mori, W.; Chaudhary, A.; Zhao, C.; Yamasaki, T.; Zhang, Z.; Feng, S.; Ware, T.; Rong, J.; Fujinaga, M.; Chen, J.; Kumata, K.; Zhang, Y.; Hu, K.; Xie, L.; Zhou, X.; Song, Z.; Gao, Y.; Sun, Z.; Patel, J. S.; Zhai, C.; Yuan, K. Y.; Collier, T. L.; Ran, C.; Collin, L.; Haider, A.; Grether, U.; Wittwer, M. B.; Cravatt, B. F.; Zhang, M.-R. and Liang, S. H. “Radiosynthesis and Evaluation of Novel 18F Labeled PET Ligands for Imaging Monoacylglycerol Lipase”, European Journal of Medicinal Chemistry, 2025, 117246. Link: https://www.sciencedirect.com/science/article/abs/pii/S022352342500011X

 

194. Rong, J. and Liang, S. H. “Novel 5,6-fused and 6,6-fused bicyclic compounds as 15-prostaglandin dehydrogenase modulators”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00010

193. Hu, Q.-L. and Liang, S. H. “Novel Cyclic Peptides Inhibiting Tumor Necrosis Factor Receptor 1 Activity”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00011

192. Zhao, T. and Liang, S. H. “Novel Pyrimidinyl Sulfonamide Derivatives as GPR17 Modulators”, ACS Medicinal Chemistry Letters, 2025, 16, 361-362. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00012

191. Xin, Z. and Liang, S. H. “Hydroquinazoline Derivatives as Novel Natriuretic Peptide Receptor 1 (NPR1) Activators”, ACS Medicinal Chemistry Letters, 2025, 16, 358-360. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00013

190. Song, Z. and Liang, S. H. “Identification of Phosphodiesterase-7 Inhibitors with Spiro[[1,3]Oxazolo[5,4-f]Quinazoline-9,1′-Cyclohexan]-7-One Scaffold for the Treatment of Chronic Fatigue”, ACS Medicinal Chemistry Letters, 2025, 16, 356–357. https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00001

189. Li, Y. and Liang, S. H. “Novel Piperazine Derivatives as Selective Antagonists of GluN2B-containing NMDARs under Acidic pH Conditions”, ACS Medicinal Chemistry Letters, 2025, 16, 354-355. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00002

188. Tan, Z.; Nie, B.; Wu, H.; Li, B.; Shang, J.; Zhang, T.; Xiao, Z.; Dong, C.; Zeng, C.; Wu, B.; Hou, L.; Guo, B.; Cheng, Y.; Gong, J.; Ye, W.; Xu, L.; Li, Y.; Li, X.; Liang, S. H.; Shan, B.; Xu, H.; Wang, L. “Brain development during the lifespan of cynomolgus monkeys”, NeuroImage, 2025, 305, 120952. Link: https://pubmed.ncbi.nlm.nih.gov/39662788/

 

187. Hu, Q.-L. and Liang, S. H. “Cyclic Peptides Targeting Granzyme B: Potential Applications as PET Imaging Agents”, ACS Medicinal Chemistry Letters, 2025, 16, 180-181. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00608

186. Zhao, T. and Liang, S. H. “Novel Tricyclic KRAS Inhibitors for the Treatment of Cancer”, ACS Medicinal Chemistry Letters, 2025, 16, 178-179. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00609

185. Li, Y. and Liang, S. H. “Novel Heterocyclic Piperazine Amide Derivatives as Alpha-synuclein PET Ligands for Diagnosis of Parkinson’s Disease”, ACS Medicinal Chemistry Letters, 2025, 16, 184-185. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00606

184. Song, Z. and Liang, S. H. “Imaging Alpha-synuclein with Novel 5H-Imidazo[1,5-b][1,2,4]triazole Radioligands for the Diagnosis of Parkinson’s Disease”, ACS Medicinal Chemistry Letters, 2025, 2025, 16, 182-183. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00607